📈 We have witnessed a huge increase in the total number of preclinical ADC drugs over the past 3 years! Of the 804 ADCs currently in preclinical development, over 70% are classed as active, demonstrating evidence of continued development and instilling developers with confidence for future advancements. If you’re finding it challenging to keep up with this constantly evolving space, then our infographic is for you! Discover top targets and moiety formats, recent trends in the disease landscape, and a breakdown of the 330 payloads being used. Download it here: https://ter.li/1fd2ac 📄 #ADCs #Preclinical #HER2 #DrugDevelopment
Beacon’s Post
More Relevant Posts
-
🚀 Join Us for an Exclusive Inside Look at RNA Drug Development Trends! Are you ready to dive into the future of RNA therapeutics? 🔬 Our upcoming webinar on October 30, 2024, at 9am PDT | 12pm EDT | 4pm GMT will explore the latest innovations shaping the landscape of RNA drug development. Register now to secure your spot! 🔗 https://ter.li/upz9fp Hosted by experts from Beacon and Hanson Wade Intelligence you'll gain valuable insights into cutting-edge delivery systems, emerging technologies, and the commercial trends redefining the RNA market. Don't miss this opportunity to stay ahead of the curve in one of biotech's fastest-growing fields. #RNADrugDevelopment #RNA #RNAdeliverysystems #oligonucleotides
-
-
Beacon extends its congratulations to Victor Ambros and Gary Ruvkun on receiving the 2024 Nobel Prize in Physiology or Medicine for their groundbreaking discovery of microRNA! 🎉 This award not only honours their incredible work but marks a pivotal moment for the future of the field. The monumental discovery has profound implications, particularly in understanding complex diseases, opening the door to more advanced treatments. Exciting times ahead for the RNA space 👏 #NobelPrize #MicroRNA #GeneRegulation
BREAKING NEWS The Nobel Assembly at the Karolinska Institutet has today decided to award the 2024 Nobel Prize in Physiology or Medicine to Victor Ambros and Gary Ruvkun for the discovery of microRNA and its role in post-transcriptional gene regulation. This year’s Nobel Prize honours two scientists for their discovery of a fundamental principle governing how gene activity is regulated. The information stored within our chromosomes can be likened to an instruction manual for all cells in our body. Every cell contains the same chromosomes, so every cell contains exactly the same set of genes and exactly the same set of instructions. Yet, different cell types, such as muscle and nerve cells, have very distinct characteristics. How do these differences arise? The answer lies in gene regulation, which allows each cell to select only the relevant instructions. This ensures that only the correct set of genes is active in each cell type. This year’s medicine laureates Victor Ambros and Gary Ruvkun were interested in how different cell types develop. They discovered microRNA, a new class of tiny RNA molecules that play a crucial role in gene regulation. Their groundbreaking discovery revealed a completely new principle of gene regulation that turned out to be essential for multicellular organisms, including humans. It is now known that the human genome codes for over one thousand microRNAs. Their surprising discovery revealed an entirely new dimension to gene regulation. MicroRNAs are proving to be fundamentally important for how organisms develop and function.
-
-
🚨 Only 1 day to go until our webinar on the latest advancements in ADCs! Novel drug conjugates are emerging as a transformative force in the ADC space so don't miss this chance to dive deep into emerging trends and cutting-edge insights with our expert speakers, Yu-Shin Hsu and Callum Angus. ⏳ Last chance to register: 🔗 https://ter.li/rzae33 Whether you're in drug development or clinical research, this is the event to stay ahead! #ADCs #noveldrugconjugates #ADCinnovation #ADCclinicalsuccess #emergingADCs Hanson Wade Intelligence
-
-
🚀 Day 1 of the #CARTCR Summit in Boston kicked things off with a fantastic start! Our Senior Research Analyst, Rachel East, delivered yet another insightful presentation to a packed room, diving deep into the current trends shaping the CAR and TCR therapy landscape. From platform innovations to competitive developments, the conversation around cutting-edge therapies is buzzing! 💡✨ Day 2 is about to kick off so make sure to visit our booth today if you are on-site to catch up with the team, grab some cool swag, and learn more about how we can help you drive innovation in this space. #cartcr #cartcrtherapies #celltherapy #drugdiscovery #drugdevelopment #clinicalresearch #preclinical #celltherapymanufacturing
-
-
⏳ One week until our upcoming webinar in collaboration with Hanson Wade Intelligence - join us to discover the latest data across promising ADC innovations! Join us to explore the cutting-edge trends in ADC innovation, global partnerships, and clinical breakthroughs. Whether you're in drug development, clinical research, or just curious about the future of ADCs, this webinar is for you! 📅 Don’t wait—secure your spot now! 🔗 https://ter.li/rzae33 #ADCs #noveldrugconjugates #ADCinnovation #ADCclinicalsuccess #emergingADCs
-
-
🚀 We were thrilled to participate in the inaugural ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit this week in Boston! Jake Morris took the stage to share key clinical and partnership developments, analyze venture investment trends in early discovery and preclinical science, and examine the growing number of global partnerships. With major moves in the pharma and biotech partnerships reshaping the landscape, there has never been a better opportunity to showcase this critical data. 📈 Want to discover how you too can navigate this complex partnering landscape with confidence? Get in touch with Jake directly or reach out to our team at beacon@hansonwade.com. #ADCPartnering #ADCs #Radiopharma #GlobalPartnerships #ADCInvestment #Biotech #ADCpartnerships #ADCpartneringlandscape Hanson Wade Group
-
-
📣 Did you know that there has been an 83% growth rate of novel drug conjugates across the ADC space, including radioconjugates, antibody-oligonucleotide conjugates, and bispecific ADCs, since 2022? Feel this exciting buzz within the space in our upcoming webinar! Register here and be part of the conversation 🔗 https://ter.li/rzae33 Join Beacon ADC's Yu-Shin Hsu and Hanson Wade Intelligence's Callum Angus for an in-depth look at the latest breakthroughs in novel drug conjugates, including diverse payloads, targets, and the rise of Bispecific ADCs and antibody degrader conjugates. Discover how these innovations advance precision medicine and enable safer, more effective therapies. Don’t miss this opportunity to comprehensively understand the future of ADCs and their role in achieving clinical breakthroughs. #ADCs #noveldrugconjugates #ADCinnovation #ADCclinicalsuccess #emergingADCs
-
